RxDoctor Payments Data

Joohi Jimenez-Shahed, MD

Neurology · Houston, TXNPI 1033299623

Payments from drug & device makers

$456,749in general payments, 2019–2025

Across 354 payments — averaging $1290.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sage Therapeutics, LLC$98K
  • Amneal Pharmaceuticals LLC$95K
  • Eli Lilly$61K
  • Teva Pharmaceuticals USA, Inc.$49K
  • Medtronic$41K
  • Sunovion Pharmaceuticals Inc.$40K
  • plus $73K from 14 others
$70,389in research payments, 2019–2025

Across 9 payments — averaging $7820.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amneal Pharmaceuticals LLC$64K
  • Eli Lilly$4K
  • Neurocrine Biosciences, Inc.$3K

What the payments were for

  • Consulting fees$104,71964%
  • Speaking & faculty fees$24,32615%
  • Travel & lodging$23,48814%
  • Food & beverage$9,6086%
  • Education$6930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$456,749 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$196,926
Medicare patients
201
Services billed
18,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa74$98,129
Carbidopa-LevodopaCarbidopa/Levodopa198$6,355
Rasagiline Mesylate31$4,906
Rivastigmine14$3,250
AmantadineAmantadine Hcl19$2,423
Propranolol Hcl ErPropranolol Hcl21$1,267
Fludrocortisone Acetate12$962
Carbidopa-Levodopa ErCarbidopa/Levodopa22$802
Memantine Hcl32$760
Ropinirole ErRopinirole Hcl21$742
Guanfacine Hcl15$435
Topiramate28$306
Propranolol Hcl17$293
Gabapentin21$232
Pregabalin14$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$94,582$98,12974 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →